Brain tumors represent the leading cause of disease-related mortality and morbidity in children, with effective treatments urgently required. One factor limiting the effectiveness of systemic therapy is the blood-brain-barrier (BBB), which limits the brain penetration of many anticancer drugs. BBB integrity is often compromised in tumors, referred to as the blood-brain-tumor-barrier (BBTB), and the impact of a compromised BBTB on the therapeutic sensitivity of brain tumors has been clearly shown for a few selected agents. However, the heterogeneity of barrier alteration observed within a single tumor and across distinct pediatric tumor types represents an additional challenge. Herein, we discuss what is known regarding the heterogeneity of tumor-associated vasculature in pediatric brain tumors. We discuss innovative and complementary preclinical model systems that will facilitate real-time functional analyses of BBTB for all pediatric brain tumor types. We believe a broader use of these preclinical models will enable us to develop a greater understanding of the processes underlying tumor-associated vasculature formation and ultimately more efficacious treatment options.
Medulloblastoma (MB) is an embryonal-derived lesion arising in the cerebellum, contributing to 20% of childhood brain tumours and 63% of intracranial embryonal tumours. Currently, standard of care includes surgical resection and chemotherapy, used in conjunction with radiation. While these treatments have significantly improved survival rates, the therapy side effects are detrimental to survivors’ quality of life. Furthermore, relapse occurs in 30% of patients and unfortunately these are untreatable and therefore fatal for 95% of patients. It is presumed that in patients that present with a recurrent tumour, initial treatment has been ineffective. A major cause of this can be the heterogenous vasculature in and around the tumour. Recent studies have identified that the blood brain barrier (BBB), in the context of MB, is highly heterogenous with differences in BBB cellular composition and integrity between MB sub-types and within single tumours. It remains unclear however, how these vascular differences emerge and what the primary defects are. This gap in our knowledge is mainly due to the lack of models that allow long-term live imaging. We have established a xenograft approach to examine human MB tumour cells in zebrafish embryonal brains. We have validated that human Medulloblastoma cells of the Group 3 (Gp3) MB subgroup, are viable in zebrafish brains. This work has also identified that in the presence of these human Gp3 MB tumour cells, the local vasculature becomes dysmorphic and tortuous over time. Timelapse imaging of these tumour and vasculature interactions demonstrates that there is a rapid and long ranging angiogenic response with new vessel sprouts growing towards the tumour cells. By utilising our large range of transgenic zebrafish lines, we will continue investigating how MB cells interact and alter distinctive BBB cell types and how these changes impact vessel function.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.